H.R. 2038 · 116th Congress
State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 116th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
R
MeadowsSponsor
State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
What it does: CRS summary · Introduced in House · Apr 2, 2019
State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
This bill authorizes health insurance issuers to jointly negotiate the prices for prescription drugs with the manufacturers of such drugs.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: State-Based, Market-Oriented, Prescription Drug Negotiations Act of 2019
Latest action (May 15, 2019): Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Policy area: Health · Origin: House · Introduced: Apr 2, 2019
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.